Wall Street hedge fund manager Steve Cohen has taken another big stake in a small publicly traded biotech company called Bionomics.

Peter Thiel has quietly bet on a relatively unknown biotech company called Bionomics that is aiming to treat PTSD.

Toronto based startup Vital Biosciences is building diagnostics technology that aims to radically change blood testing.

Biotech IPOs have been extremely quiet, but these large new public listings show some renewed momentum in the public markets for drug discovery.

With at home cancer screening kits, CleanCard is bringing together biology and computation to create first of its kind diagnostics.

ExcepGen, a San Francisco based biotech company, has emerged from stealth to announce $14 million in seed funding from some of the brightest investors in Silico

Amber Bio, a San Francisco based developer of gene editing platforms to reach undruggable diseases, announced $26M in funding.